keyword
MENU ▼
Read by QxMD icon Read
search

Mri alzheimer

keyword
https://www.readbyqxmd.com/read/29786594/-brain-microbleeds-definition-pathophysiology-and-the-consequences
#1
Marek Mazurek, Ewa Papuć, Konrad Rejdak
Brain microbleeds are defined as small, circular hypointense changes in T2-sequensec of brain MRI, well demarcated from the surrounding tissue. They represent the phagocytized products of blood distribution extravasated from pathologically altered vessels. The echo-T2-dependent gradient (GRE) and magnetic susceptibility testing (SWI) sequences are usually used to visualize them. The pathogenesis of microbleeds very complex but angiopathy associated with arterial hypertension and cerebral amyloid angiopathy play a special role...
2018: Wiadomości Lekarskie: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/29785624/longitudinal-neuroimaging-hippocampal-markers-for-diagnosing-alzheimer-s-disease
#2
Carlos Platero, Lin Lin, M Carmen Tobar
Hippocampal atrophy measures from magnetic resonance imaging (MRI) are powerful tools for monitoring Alzheimer's disease (AD) progression. In this paper, we introduce a longitudinal image analysis framework based on robust registration and simultaneous hippocampal segmentation and longitudinal marker classification of brain MRI of an arbitrary number of time points. The framework comprises two innovative parts: a longitudinal segmentation and a longitudinal classification step. The results show that both steps of the longitudinal pipeline improved the reliability and the accuracy of the discrimination between clinical groups...
May 21, 2018: Neuroinformatics
https://www.readbyqxmd.com/read/29784544/classifying-alzheimer-s-disease-with-brain-imaging-and-genetic-data-using-a-neural-network-framework
#3
Kaida Ning, Bo Chen, Fengzhu Sun, Zachary Hobel, Lu Zhao, Will Matloff, Arthur W Toga
A long-standing question is how to best use brain morphometric and genetic data to distinguish Alzheimer's disease (AD) patients from cognitively normal (CN) subjects and to predict those who will progress from mild cognitive impairment (MCI) to AD. Here, we use a neural network (NN) framework on both magnetic resonance imaging-derived quantitative structural brain measures and genetic data to address this question. We tested the effectiveness of NN models in classifying and predicting AD. We further performed a novel analysis of the NN model to gain insight into the most predictive imaging and genetics features and to identify possible interactions between features that affect AD risk...
April 24, 2018: Neurobiology of Aging
https://www.readbyqxmd.com/read/29782314/a-retrospective-belgian-multi-center-mri-biomarker-study-in-alzheimer-s-disease-remember
#4
Ellis Niemantsverdriet, Annemie Ribbens, Christine Bastin, Florence Benoit, Bruno Bergmans, Jean-Christophe Bier, Roxanne Bladt, Lene Claes, Peter Paul De Deyn, Olivier Deryck, Bernard Hanseeuw, Adrian Ivanoiu, Jean-Claude Lemper, Eric Mormont, Gaëtane Picard, Eric Salmon, Kurt Segers, Anne Sieben, Dirk Smeets, Hanne Struyfs, Evert Thiery, Jos Tournoy, Eric Triau, Anne-Marie Vanbinst, Jan Versijpt, Maria Bjerke, Sebastiaan Engelborghs
BACKGROUND: Magnetic resonance imaging (MRI) acquisition/processing techniques assess brain volumes to explore neurodegeneration in Alzheimer's disease (AD). OBJECTIVE: We examined the clinical utility of MSmetrix and investigated if automated MRI volumes could discriminate between groups covering the AD continuum and could be used as a predictor for clinical progression. METHODS: The Belgian Dementia Council initiated a retrospective, multi-center study and analyzed whole brain (WB), grey matter (GM), white matter (WM), cerebrospinal fluid (CSF), cortical GM (CGM) volumes, and WM hyperintensities (WMH) using MSmetrix in the AD continuum...
May 16, 2018: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/29781630/mental-orientation-a-new-approach-to-assessing-patients-across-the-alzheimer-s-disease-spectrum
#5
Gregory Peters-Founshtein, Michael Peer, Yanai Rein, Shlomzion Kahana Merhavi, Zeev Meiner, Shahar Arzy
OBJECTIVE: This study aims to assess the role of mental-orientation in the diagnosis of mild cognitive impairment and Alzheimer's disease using a novel task. METHOD: A behavioral study (Experiment 1) compared the mental-orientation task to standard neuropsychological tests in patients across the Alzheimer's disease spectrum. A functional MRI study (Experiment 2) in young adults compared activations evoked by the mental-orientation and standard-orientation tasks as well as their overlap with brain regions susceptible to Alzheimer's disease pathology...
May 21, 2018: Neuropsychology
https://www.readbyqxmd.com/read/29780348/spatiotemporal-propagation-of-the-cortical-atrophy-population-and-individual-patterns
#6
Igor Koval, Jean-Baptiste Schiratti, Alexandre Routier, Michael Bacci, Olivier Colliot, Stéphanie Allassonnière, Stanley Durrleman
Repeated failures in clinical trials for Alzheimer's disease (AD) have raised a strong interest for the prodromal phase of the disease. A better understanding of the brain alterations during this early phase is crucial to diagnose patients sooner, to estimate an accurate disease stage, and to give a reliable prognosis. According to recent evidence, structural alterations in the brain are likely to be sensitive markers of the disease progression. Neuronal loss translates in specific spatiotemporal patterns of cortical atrophy, starting in the enthorinal cortex and spreading over other cortical regions according to specific propagation pathways...
2018: Frontiers in Neurology
https://www.readbyqxmd.com/read/29777006/in-vivo-characterization-and-quantification-of-neurofibrillary-tau-pet-radioligand-18-f-mk-6240-in-humans-from-alzheimer-s-disease-dementia-to-young-controls
#7
Tobey J Betthauser, Karly A Cody, Matthew D Zammit, Dhanabalan Murali, Alexander K Converse, Todd E Barnhart, Charles K Stone, Howard A Rowley, Sterling C Johnson, Bradley T Christian
Tau positron emission tomography (PET) imaging has potential for elucidating changes in the deposition of neuropathological tau aggregates that are occurring during the progression of Alzheimer's disease (AD). This work investigates in vivo kinetics, quantification strategies and imaging characteristics of a novel tau PET radioligand [18 F]MK-6240 in humans. Methods: Fifty-one individuals ranging from cognitively normal young controls to persons with dementia underwent T1-weighted magnetic resonance imaging (MRI), and [11 C]PiB and [18 F]MK-6240 PET imaging...
May 18, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29776894/amyloid-pet-in-neurodegenerative-diseases-with-dementia
#8
V Camacho, A Gómez-Grande, P Sopena, D García-Solís, M Gómez Río, C Lorenzo, S Rubí, J Arbizu
Alzheimer's disease (AD) is a neurodegenerative condition characterized by progressive cognitive decline and memory loss, and is the most common form of dementia. Amyloid plaques with neurofibrillary tangles are a neuropathological hallmark of AD that produces synaptic dysfunction and culminates later in neuronal loss. Amyloid PET is a useful, available and non-invasive technique that provides in vivo information about the cortical amyloid burden. In the latest revised criteria for the diagnosis of AD biomarkers were defined and integrated: pathological and diagnostic biomarkers (increased retention on fibrillar amyloid PET or decreased Aβ1-42 and increased T-Tau or P-Tau in CSF) and neurodegeneration or topographical biomarkers (temporoparietal hypometabolism on 18 F-FDG PET and temporal atrophy on MRI)...
May 15, 2018: Revista Española de Medicina Nuclear e Imagen Molecular
https://www.readbyqxmd.com/read/29766613/cortical-thickness-estimations-of-freesurfer-and-the-cat12-toolbox-in-patients-with-alzheimer-s-disease-and-healthy-controls
#9
Rene Seiger, Sebastian Ganger, Georg S Kranz, Andreas Hahn, Rupert Lanzenberger
BACKGROUND AND PURPOSE: Automated cortical thickness (CT) measurements are often used to assess gray matter changes in the healthy and diseased human brain. The FreeSurfer software is frequently applied for this type of analysis. The computational anatomy toolbox (CAT12) for SPM, which offers a fast and easy-to-use alternative approach, was recently made available. METHODS: In this study, we compared region of interest (ROI)-wise CT estimations of the surface-based FreeSurfer 6 (FS6) software and the volume-based CAT12 toolbox for SPM using 44 elderly healthy female control subjects (HC)...
May 15, 2018: Journal of Neuroimaging: Official Journal of the American Society of Neuroimaging
https://www.readbyqxmd.com/read/29765316/noradrenergic-dysfunction-in-alzheimer-s-and-parkinson-s-diseases-an-overview-of-imaging-studies
#10
REVIEW
Andrew C Peterson, Chiang-Shan R Li
Noradrenergic dysfunction contributes to cognitive impairment in Alzheimer's Disease (AD) and Parkinson's Disease (PD). Conventional therapeutic strategies seek to enhance cholinergic and dopaminergic neurotransmission in AD and PD, respectively, and few studies have examined noradrenergic dysfunction as a target for medication development. We review the literature of noradrenergic dysfunction in AD and PD with a focus on human imaging studies that implicate the locus coeruleus (LC) circuit. The LC sends noradrenergic projections diffusely throughout the cerebral cortex and plays a critical role in attention, learning, working memory, and cognitive control...
2018: Frontiers in Aging Neuroscience
https://www.readbyqxmd.com/read/29762152/alzheimer-s-disease-neuroimaging
#11
Jennifer L Whitwell
PURPOSE OF REVIEW: The aim of this study was to discuss the contribution of neuroimaging studies to our understanding of Alzheimer's disease. We now have the capability of measuring both tau and beta-amyloid (Aβ) proteins in the brain, which together with more traditional neuroimaging modalities, has led the field to focus on using neuroimaging to better characterize disease mechanisms underlying Alzheimer's disease. RECENT FINDINGS: Studies have utilized tau and Aβ PET, as well as [18F]fluorodeoxyglucose PET, and structural and functional MRI, to investigate the following topics: phenotypic variability in Alzheimer's disease , including how neuroimaging findings are related to clinical phenotype and age; multimodality analyses to investigate the relationships between different neuroimaging modalities and what that teaches us about disease mechanisms; disease staging by assessing neuroimaging changes in the very earliest phases of the disease in cognitively normal individuals and individuals carrying an autosomal dominant Alzheimer's disease mutation; and influence of other comorbidities and proteins to the disease process...
May 11, 2018: Current Opinion in Neurology
https://www.readbyqxmd.com/read/29762090/alzheimer-disease-and-mild-cognitive-impairment-integrated-pulsed-arterial-spin-labeling-mri-and-18-f-fdg-pet
#12
Isabelle Riederer, Karl Peter Bohn, Christine Preibisch, Eva Wiedemann, Claus Zimmer, Panagiotis Alexopoulos, Stefan Förster
Purpose To compare PET/MR hypoperfusion and hypometabolism in patients with Alzheimer disease (AD) and mild cognitive impairment (MCI) compared with healthy control (HC) participants. Materials and Methods Maps of cerebral blood flow (CBF; pulsed arterial spin-labeling [ASL] MRI), glucose metabolism (fluorine 18 [18 F] fluorodeoxyglucose [FDG] PET), and gray matter (GM) volume (structural T1-weighted MRI) were calculated from integrated PET/MR data in 45 patients with AD (mean age, 69 years ± 9 [standard deviation]; age range, 51-89 years), 20 patients with MCI (mean age, 64 years ± 10; age range, 45-82 years), and 11 HC participants (mean age, 65 years ± 8; age range, 54-80 years) between 2011 and 2014...
May 15, 2018: Radiology
https://www.readbyqxmd.com/read/29760644/an-algorithm-for-preclinical-diagnosis-of-alzheimer-s-disease
#13
REVIEW
Tapan K Khan
Almost all Alzheimer's disease (AD) therapeutic trials have failed in recent years. One of the main reasons for failure is due to designing the disease-modifying clinical trials at the advanced stage of the disease when irreversible brain damage has already occurred. Diagnosis of the preclinical stage of AD and therapeutic intervention at this phase, with a perfect target, are key points to slowing the progression of the disease. Various AD biomarkers hold enormous promise for identifying individuals with preclinical AD and predicting the development of AD dementia in the future, but no single AD biomarker has the capability to distinguish the AD preclinical stage...
2018: Frontiers in Neuroscience
https://www.readbyqxmd.com/read/29760643/combining-polygenic-hazard-score-with-volumetric-mri-and-cognitive-measures-improves-prediction-of-progression-from-mild-cognitive-impairment-to-alzheimer-s-disease
#14
Karolina Kauppi, Chun Chieh Fan, Linda K McEvoy, Dominic Holland, Chin Hong Tan, Chi-Hua Chen, Ole A Andreassen, Rahul S Desikan, Anders M Dale
Improved prediction of progression to Alzheimer's Disease (AD) among older individuals with mild cognitive impairment (MCI) is of high clinical and societal importance. We recently developed a polygenic hazard score (PHS) that predicted age of AD onset above and beyond APOE . Here, we used data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) to further explore the potential clinical utility of PHS for predicting AD development in older adults with MCI. We examined the predictive value of PHS alone and in combination with baseline structural magnetic resonance imaging (MRI) data on performance on the Mini-Mental State Exam (MMSE)...
2018: Frontiers in Neuroscience
https://www.readbyqxmd.com/read/29755611/morphological-biomarker-differentiating-mci-converters-from-nonconverters-longitudinal-evidence-based-on-hemispheric-asymmetry
#15
Xiaojing Long, Chunxiang Jiang, Lijuan Zhang
Identifying subjects with mild cognitive impairment (MCI) who may probably progress to Alzheimer's disease (AD) is important for better understanding the disease mechanisms and facilitating early treatments. In addition to the direct volumetric and thickness measurement based on high-resolution magnetic resonance imaging (MRI), hemispheric asymmetry could be a potential index to detect morphological variations in MCI patients with a high risk of conversion to AD. The present study collected a set of longitudinal MRI data from 53 MCI converters and nonconverters and investigated the asymmetry differences between groups...
2018: Behavioural Neurology
https://www.readbyqxmd.com/read/29752765/adaptive-template-generation-for-amyloid-pet-using-a-deep-learning-approach
#16
Seung Kwan Kang, Seongho Seo, Seong A Shin, Min Soo Byun, Dong Young Lee, Yu Kyeong Kim, Dong Soo Lee, Jae Sung Lee
Accurate spatial normalization (SN) of amyloid positron emission tomography (PET) images for Alzheimer's disease assessment without coregistered anatomical magnetic resonance imaging (MRI) of the same individual is technically challenging. In this study, we applied deep neural networks to generate individually adaptive PET templates for robust and accurate SN of amyloid PET without using matched 3D MR images. Using 681 pairs of simultaneously acquired 11 C-PIB PET and T1-weighted 3D MRI scans of AD, MCI, and cognitively normal subjects, we trained and tested two deep neural networks [convolutional auto-encoder (CAE) and generative adversarial network (GAN)] that produce adaptive best PET templates...
May 11, 2018: Human Brain Mapping
https://www.readbyqxmd.com/read/29752653/imaging-neurodegeneration-in-down-syndrome-brain-templates-for-amyloid-burden-and-tissue-segmentation
#17
Patrick J Lao, Ben L Handen, Tobey J Betthauser, Karly A Cody, Annie D Cohen, Dana L Tudorascu, Charles K Stone, Julie C Price, Sterling C Johnson, William E Klunk, Bradley T Christian
The focus of Alzheimer's disease (AD) neuroimaging research has shifted towards an investigation of the earliest stages of AD pathogenesis, which manifests in every young adult with Down syndrome (DS; trisomy 21) resulting from a deterministic genetic predisposition to amyloid precursor protein overproduction. Due to morphological differences in brain structure in the DS population, special consideration must be given to processing pipelines and the use of normative atlases developed for the non-DS population...
May 11, 2018: Brain Imaging and Behavior
https://www.readbyqxmd.com/read/29752516/dual-tracer-tau-pet-imaging-reveals-different-molecular-targets-for-11-c-thk5351-and-11-c-pbb3-in-the-alzheimer-brain
#18
Konstantinos Chiotis, Per Stenkrona, Ove Almkvist, Vladimir Stepanov, Daniel Ferreira, Ryosuke Arakawa, Akihiro Takano, Eric Westman, Andrea Varrone, Nobuyuki Okamura, Hitoshi Shimada, Makoto Higuchi, Christer Halldin, Agneta Nordberg
PURPOSE: Several tau PET tracers have been developed, but it remains unclear whether they bind to the same molecular target on the heterogeneous tau pathology. In this study we evaluated the binding of two chemically different tau-specific PET tracers (11 C-THK5351 and 11 C-PBB3) in a head-to-head, in vivo, multimodal design. METHODS: Nine patients with a diagnosis of mild cognitive impairment or probable Alzheimer's disease and cerebrospinal fluid biomarker evidence supportive of the presence of Alzheimer's disease brain pathology were recruited after thorough clinical assessment...
May 12, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29746400/mri-of-non-alzheimer-s-dementia-current-and-emerging-knowledge
#19
Massimo Filippi, Federica Agosta
PURPOSE OF REVIEW: The correct classification of non-Alzheimer's dementia is crucial to study disease mechanisms, predict disease progression and test disease-specific treatments. Brain atrophy assessment with morphometric MRI is currently the gold standard for in-vivo localization of neurodegeneration. Structural and functional connectivity biomarkers are becoming increasingly available. This review emphasizes the potential applications of MRI in the main non-Alzheimer's dementia such as dementia with Lewy bodies (DLB) and frontotemporal dementia (FTD)...
May 8, 2018: Current Opinion in Neurology
https://www.readbyqxmd.com/read/29745510/-detection-algorithm-of-amyloid-%C3%AE-protein-deposition-in-magnetic-resonance-image-based-on-pixel-feature-learning-method
#20
Fang Yan, Yongming Li, Xueru Zhu, Jie Wang, Pin Wang, Fan Li, Mingguo Qiu, Jian Qin
Amyloid β-protein (Aβ) deposition is an important prevention and treatment target for Alzheimer's disease (AD), and early detection of Aβ deposition in the brain is the key to early diagnosis of AD. Magnetic resonance imaging (MRI) is the perfect imaging technology for the clinical diagnosis of AD, but it cannot display the plaque deposition directly. In this paper, based on two feature selection modes-filter and wrapper, chain-like agent genetic algorithm (CAGA), principal component analysis (PCA), support vector machine (SVM) and random forest (RF), we designed six kinds of feature learning classification algorithms to detect the information (distribution) of Aβ deposition through magnetic resonance image pixels selection...
June 1, 2017: Sheng Wu Yi Xue Gong Cheng Xue za Zhi, Journal of Biomedical Engineering, Shengwu Yixue Gongchengxue Zazhi
keyword
keyword
44318
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"